Minor ailments

Urinary tract infections (uncomplicated)

Ontario assessment · Screening, treatment, documentation and follow-up

Clinical evidence & sources

Clinical basis & sources

Content last reviewed . Spot something outdated? Use the correction link at the bottom of the page.

Allowable drugs under Schedule 4 (4)

Drugs an Ontario pharmacist may prescribe for Urinary tract infections (uncomplicated) under O. Reg. 256/24, Schedule 4. Choice still depends on the assessment, contraindications, allergies, and product availability — this is the eligible list, not a recommendation.

  • Fosfomycin
  • Nitrofurantoin
  • Sulfamethoxazole
  • Trimethoprim
Latest targeted source check · Oct 5, 2026

Targeted check of Canadian product and treatment details against the sources below; not an exhaustive DIN-by-DIN review or a guarantee of stock. Confirm the selected product label and patient suitability.

1

Visit details

Confirm age, answer the questions and record consent

As confirmed with the patient; months for a baby.

You can continue without entering these details. When prescribing, notify the patient's family doctor or primary care provider if they have one. Leaving these fields blank does not remove that responsibility; preparing a notice does not send it.

Sex at birthRequired

Pregnant or breastfeeding?Required

Episodes this yearRequired

Symptom onsetRequired

Pharmacy not set
2

Presentation and eligibility

Select the symptoms and checks that apply

Presenting symptoms or exposure

Eligibility criteria

Assessment checks

Onset

Severity

3

Safety check

Required: confirm no red flags, or select every red flag present

Before confirming no red flags

  • • Asymptomatic bacteriuria should NOT be treated — especially in older adults, where positive dipstick without symptoms is common and not infection.
  • • Tighten exclusions: male patient, pregnancy, pyelonephritis symptoms (flank pain, fever, vomiting), recurrent, indwelling catheter, recent antibiotic course, known resistance.
  • • TMP-SMX: screen for hyperkalemia risk (ACEi/ARB/spironolactone, CKD) and warfarin interaction (INR spike) before prescribing.
  • • Reassess at 48–72 h; if no improvement, switch agent or refer.
4

Treatment

Select each medicine or self-care option you want in the plan

Finish the assessment first. Treatment opens when steps 1 to 3 are complete.

5

Follow-up

Sets the reminder and the documents

Phone or in-person check-in 2-3 days after starting treatment to confirm symptom resolution and identify treatment failure.

Use the pathway guidance and your assessment to choose the interval. This choice updates the documents; add a reminder to see it in your follow-up list.

Send a suggestion or correction

Tell us what should change on the Urinary tract infections (uncomplicated) page.

Do not include patient names, health card numbers, prescription numbers, or other identifying information.